Skip to main content
Log in

Hypertension in 2011

New insights—from risk factors to treatment implications

  • Year in Review
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

The results of several hypertension studies published in 2011 have contributed to our knowledge on the risks of and treatment for this condition, including the effects of slow-wave sleep, nocturnal dosing of medication, variability in post-stroke blood-pressure reduction, and the impacts of a low-sodium diet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hermida, R. C., Ayala, D. E., Mojon, A. & Fernandez, J. R. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J. Am. Soc. Nephrol. 10.1681/ASN.2011040361.

  2. Minutolo, R. et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am. J. Kidney Dis. 50, 908–917 (2007).

    Article  PubMed  Google Scholar 

  3. Rahman, M. & Appel, L. J. Should reducing nocturnal blood pressure be a therapeutic target in CKD? The time is ripe for a clinical outcomes trial. Am. J. Kidney Dis. 50, 901–903 (2007).

    Article  PubMed  Google Scholar 

  4. Black, H. R. et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289, 2073–2082 (2003).

    Article  CAS  PubMed  Google Scholar 

  5. Fung, M. M. et al. Decreased slow wave sleep increases risk of developing hypertension in elderly men. Hypertension 58, 596–603 (2011).

    Article  CAS  PubMed  Google Scholar 

  6. Sandset, E. C. et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377, 741–750 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Aiyagari, V. & Gorelick, P. B. Management of blood pressure for acute and recurrent stroke. Stroke 40, 2251–2256 (2009).

    Article  PubMed  Google Scholar 

  8. Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L. & Ebrahim, S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am. J. Hypertens. 24, 843–853 (2011).

    Article  CAS  PubMed  Google Scholar 

  9. Bibbins-Domingo, K. et al. Projected effect of dietary salt reductions on future cardiovascular disease. N. Engl. J. Med. 362, 590–599 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

G. L. Bakris has received grants/research support from Forest laboratories, Medtronic, Novartis, and Relypsa. He has acted as a consultant for Abbott, CVRx, Eli Lilly, FDA, Johnson & Johnson, Novartis, Servier, and Takeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bakris, G. New insights—from risk factors to treatment implications. Nat Rev Cardiol 9, 75–77 (2012). https://doi.org/10.1038/nrcardio.2011.202

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2011.202

  • Springer Nature Limited

This article is cited by

Navigation